Oral ketamine vs placebo in patients with cancer-related neuropathic pain

Tools

Fallon, Marie T., Wilcock, Andrew, Kelly, Caroline A., Paul, James, Lewsley, Liz-Anne, Norrie, John and Laird, Barry J. A. (2018) Oral ketamine vs placebo in patients with cancer-related neuropathic pain. JAMA Oncology . ISSN 2374-2437

[thumbnail of jamaoncology_Fallon_2018_ld_180004.pdf]
Preview
 PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Available under Licence Creative Commons Attribution.
Download (198kB) | Preview

Abstract

Ketamine hydrochloride is used as an adjuvant treatment for cancer-related neuropathic pain, but evidence of its effectiveness is limited.1 Findings of a large trial investigating the use of ketamine for general cancer pain were negative, but the population studied did not specifically have neuropathic pain. A randomized trial of oral ketamine for cancer-related neuropathic pain has been called for, and the present trial addresses that need.

Item Type: Article
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences
Identification Number: 10.1001/jamaoncol.2018.0131
Depositing User: Eprints, Support
Date Deposited: 16 Apr 2018 10:37
Last Modified: 17 Apr 2018 04:27
URI: https://eprints.nottingham.ac.uk/id/eprint/51161

Actions (Archive Staff Only)

Edit View Edit View